New antifungal drugs and the pediatric cancer patient: Current status of clinical development

Klinische Padiatrie

Volumn 217, Issue 3, 2005, Pages 158-168

  Groll, Andreas H ^a   Lehrnbecher, T ^b  

^a UNIVERSITY HOSPITAL MÜNSTER   (Germany)

^b UNIVERSITY HOSPITAL FRANKFURT   (Germany)

Author keywords

Antifungal agents; Cancer; Caspofungin; Children; Mycoses; Voriconazole

Indexed keywords

AMPHOTERICIN B; AMPHOTERICIN B DEOXYCHOLATE; ANIDULAFUNGIN; ANTIFUNGAL AGENT; ASTEMIZOLE; BENZODIAZEPINE DERIVATIVE; CARBAMAZEPINE; CASPOFUNGIN; CISAPRIDE; CYCLOSPORIN; DEXAMETHASONE; EFAVIRENZ; ERGOTAMINE; FLUCONAZOLE; INDINAVIR; ITRACONAZOLE; MICAFUNGIN; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; NELFINAVIR; NEVIRAPINE; OMEPRAZOLE; PHENOBARBITAL; PHENYTOIN; PIMOZIDE; POSACONAZOLE; PROTEINASE INHIBITOR; QUINIDINE; RAPAMYCIN; RAVUCONAZOLE; RIFABUTIN; RIFAMPICIN; RNA DIRECTED DNA POLYMERASE INHIBITOR; STATIN; SULFONYLUREA DERIVATIVE; TACROLIMUS; TERFENADINE; TRIAZOLE DERIVATIVE; VINCA ALKALOID; VORICONAZOLE; WARFARIN;

ANTIFUNGAL ACTIVITY; CANCER PATIENT; CHILDHOOD CANCER; CONFUSION; FACE EDEMA; FEVER; GASTROINTESTINAL SYMPTOM; HALLUCINATION; HEADACHE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; IMMUNE DEFICIENCY; MYCOSIS; NEPHROTOXICITY; NEUTROPENIA; PLASMA HALF LIFE; PRURITUS; RASH; REVIEW; SIDE EFFECT; SKIN MANIFESTATION; VISUAL DISORDER; VISUAL IMPAIRMENT;

ADOLESCENT; ADULT; AGE FACTORS; ANTIFUNGAL AGENTS; CHILD; CHILD, PRESCHOOL; COHORT STUDIES; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; IMMUNOCOMPROMISED HOST; MULTICENTER STUDIES; MYCOSES; NEOPLASMS; PEPTIDES, CYCLIC; PYRIMIDINES; RANDOMIZED CONTROLLED TRIALS; TRIAZOLES;

EID: 18944362878     PISSN: 03008630     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-2005-836502     Document Type: Review

References (80)

1. Ally R, Schurmann D, Kreisel W, Carosi G, Aguirrebengoa K, Dupont B, Hodges M, Troke P, Romero AJ. A randomized, double-blind, double-dummy, multicenter trial of voriconazole and fluconazole in the treatment of esophageal candidiasis in immunocompromised patients. Clin Infect Dis 2001; 33: 1447-1454
2. Andes D, Marchillo K, Stamstad T, Conklin R. In vivo pharmacokinetics and pharmacodynamics of a new triazole, voriconazole, in a murine candidiasis model. Antimicrob Agents Chemother 2003; 47: 3165-3169
3. Arathoon EG, Gotuzzo E, Noriega LM, Berman RS, DiNubile MJ, Sable CA. Randomized, double-blind, multicenter study of caspofungin versus amphotericin B for treatment of oropharyngeal and esophageal candidiases. Antimicrob Agents Chemother 2002; 46: 451-457
4. Baden LR, Katz JT, Fishman JA, Koziol C, DelVecchio A, Doran M, Rubin RH. Salvage therapy with voriconazole for invasive fungal infections in patients failing or intolerant to standard antifungal therapy. Transplantation 2003; 76: 1632-1637
5. Balani SK, Xu X, Arisen BH, Silva MV, Gries A, DeLuna FA, Cui D, Kari PH, Ly T, Hop CE, Singh R, Wallace MA, Dean DC, Lin JH, Pearson PG, Baillie TA. Metabolites of caspofungin acetate, a potent antifungal agent, in human plasma and urine. Drug Metab Dispos 2000; 28: 1274-1278
6. th Interscience Conference on Antimicrobial Agents and Chemotherapy. Abstract J-1621. American Society for Microbiology, Washington, DC 2001; 392
7. th Interscience Conference on Antimicrobial Agents and Chemotherapy. Abstract A-34. American Society for Microbiology, Washington, DC 2004; 8
8. Boucher HW, Groll AH, Chiou CC, Walsh TJ. Newer systemic antifungal agents: pharmacokinetics, safety and efficacy. Drugs 2004; 64: 1997-2020
9. Bowden R, Chadrasekar P, White MH, Li X, Pietrelli L, Gurwith M, Burik JA van, Laverdiere M, Safrin S, Wingard JR. A double-blind, randomized, controlled trial of amphotericin B colloidal dispersion versus amphotericin B for treatment of invasive aspergillosis in immunocompromised patients. Clin Infect Dis 2002; 35: 359-366
10. Bowman JC, Hicks PS, Kurtz MB, Rosen H, Schmatz DM, Liberator PA, Douglas CM. The antifungal echinocandin caspofungin acetate kills growing cells of Aspergillus fumigatus in vitro. Antimicrob Agents Chemother 2002; 46: 3001-3012
11. Caspofungin package circular. Cancidas (Fachinformation). Version 11/2004. BPI, Aulendorf, Germany 2004
12. Courtney R, Pai S, Laughlin M, Lim J, Batra V. Pharmacokinetics, safety, and tolerability of oral posaconazole administered in single and multiple doses in healthy adults. Antimicrob Agents Chemother 2003; 47: 2788-2795
13. Dannaoui E, Meletiadis J, Mouton JW, Meis JF, Verweij PE, Eurofung Network. In vitro susceptibilities of zygomycetes to conventional and new antifungals. J Antimicrob Chemother 2003; 51: 45-52
14. de Wet N, Llanos-Cuentas A, Suleiman J, Baraldi E, Krantz EF, Della Negra M, Diekmann-Berndt H. A randomized, double-blind, parallel-group, dose-response study of micafungin compared with fluconazole for the treatment of esophageal candidiasis in HIV-positive patients. Clin Infect Dis 2004; 39: 842-849
15. Denning DW, Ribaud P, Milpied N, Caillot D, Herbrecht R, Thiel E, Haas A, Ruhnke M, Lode H. Efficacy and safety of voriconazole in the treatment of acute invasive aspergillosis. Clin Infect Dis 2002; 34: 563-571
16. Denning DW. Echinocandin antifungal drugs. Lancet 2003; 362: 1142-1151
17. Ernst EJ, Klepser ME, Ernst ME, Messer SA, Pfaller MA. In vitro pharmacodynamic properties of MK-0991 determined by time-kill methods. Diagn Microbiol Infect Dis 1999; 33: 75-80
18. Franklin JA, McCormick J, Flynn PM. Retrospective study of the safety of caspofungin in immunocompromised pediatric patients. Pediatr Infect Dis J 2003; 22: 747-749
19. th Interscience Conference on Antimicrobial Agents and Chemotherapy. Abstract 839. American Society for Microbiology, Washington, DC 2000; 22
20. rd Interscience Conference on Antimicrobial Agents and Chemotherapy. Abstract M-1757. American Society for Microbiology, Washington, DC 2003; 476
21. Groll AH, Gea-Banacloche JC, Glasmacher A, Just-Nuebling G, Maschmeyer G, Walsh TJ. Clinical pharmacology of antifungal compounds. Infect Dis Clin North Am 2003; 17: 159-191
22. Groll AH, Piscitelli SC, Walsh TJ. Clinical pharmacology of systemic antifungal agents: a comprehensive review of agents in clinical use, current investigational compounds, and putative targets for antifungal drug development. Adv Pharmacol 1998; 44: 343-500
23. Groll AH, Ritter J, Muller FM. Prevention of fungal infections in children and adolescents with cancer. Klin Padiatr 2001; 213 (Suppl 1): A50-A68
24. Groll AH, Walsh TJ. Caspofungin: pharmacology, safety and therapeutic potential in superficial and invasive fungal infections. Expert Opin Investig Drugs 2001; 10: 1545-1558
25. Groll AH, Walsh TJ. Cell wall synthesis inhibitors. In: Dismukes WE, Pappas PG, Sobel JD (eds). Oxford Textbook of Clinical Mycology. Oxford University Press, New York, NY 2003; 88-103
26. Groll AH, Walsh TJ. Uncommon opportunistic fungi: new nosocomial threats. Clin Microbiol Infect 2001; 7 (Suppl 2): 8-24
27. th International Conference on Antimicrobial Agents and Chemotherapy. Abstr. 1109. American Society for Microbiology, Washington, D.C. 2000; 372
28. Hegener P, Troke PF, Fatkenheuer G, Diehl V, Ruhnke M. Treatment of fluconazole-resistant candidiasis with voriconazole in patients with AIDS. AIDS 1998; 12: 2227-2228
29. Herbrecht R, Denning DW, Patterson TF, Bennett JE, Greene RE, Oestmann JW, Kern WV, Marr KA, Ribaud P, Lortholary O, Sylvester R, Rubin RH, Wingard JR, Stark P, Durand C, Caillot D, Thiel E, Chandrasekar PH, Hodges MR, Schlamm HT, Troke PF, de Pauw B, Invasive Fungal Infections Group of the European Organisation for Research and Treatment of Cancer and the Global Aspergillus Study Group. Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis. N Engl J Med 2002; 347: 408-415
30. Hoffman HL, Ernst EJ, Klepser ME. Novel triazole antifungal agents. Expert Opin Investig Drugs 2000; 9: 593-605
31. Johnson LB, Kauffman CA. Voriconazole: a new triazole antifungal agent. Clin Infect Dis 2003; 36: 630-637
32. Klepser ME, Malone D, Lewis RE, Ernst EJ, Pfaller MA. Evaluation of voriconazole pharmacodynamics using time-kill methodology. Antimicrob Agents Chemother 2000; 44: 1917-1920
33. Kolve H, Lehrnbecher T, Ehlert K, Paulussen M, Bielack S, Vormoor J, Walsh TJ, Groll AH. Safety, tolerance and plasma concentrations of voriconazole in immunocompromised pediatric patients (abstract). Clin Microbiol Infect 2004; 10 (Suppl 3): 40-41
34. Krause DS, Reinhardt J, Vazquez JA, Reboli A, Goldstein BP, Wible M, Henkel T Anidulafungin Invasive Candidiasis Study Group. Phase 2, randomized, dose-ranging study evaluating the safety and efficacy of anidulafungin in invasive candidiasis and candidemia. Antimicrob Agents Chemother 2004; 48: 2021-2024
35. Krause DS, Simjee AE, Rensburg C van, Viljoen J, Walsh TJ, Goldstein BP, Wible M, Henkel T. A randomized, double-blind trial of anidulafungin versus fluconazole for the treatment of esophageal candidiasis. Clin Infect Dis 2004; 39: 770-775
36. Krieter P, Flannery B, Musick T, Gohdes M, Martinho M, Courtney R. Disposition of posaconazole following single-dose oral administration in healthy subjects. Antimicrob Agents Chemother 2004; 48: 3543-3551
37. th Interscience Conference on Antimicrobial Agents and Chemotherapy. Abstract A-41. American Society for Microbiology, Washington, DC 2004: 10
38. Kullberg BJ, Pappas P, Ruhnke M, Viscoli C, Cleary JD, Rubinstein E, Church LWP, Brown JM, Rex JH, Hilton F, Oborska I, Hodges M, Schlamm HAT, Sobel J. Voriconazole compared with a strategy of amphotericin B followed by fluconazole for treatment of candidemia in nonneutropenic patients (abstract). Clin Microbiol Infect 2004; 10 (Suppl 3): 41
39. Kurtz MB, Douglas CM. Lipopeptide inhibitors of fungal glucan synthase. J Med Vet Mycol 1997; 35: 79-86
40. th Interscience Conference on Antimicrobial Agents and Chemotherapy. Abstr. M-1019. American Society for Microbiology, Washington, DC 2004; 414
41. Lehrnbecher T, Groll AH, Chanock SJ. Treatment of fungal infections in neutropenic children. Curr Opin Pediatr 1999; 11: 47-55
42. rd Interscience Conference on Antimicrobial Agents and Chemotherapy. Abstract A-1572. American Society for Microbiology, Washington, DC 2003; 31
43. Maertens J, Raad I, Petrikkos G, Boogaerts M, Selleslag D, Petersen FB, Sable CA, Kartsonis NA, Ngai A, Taylor A, Patterson TF, Denning DW, Walsh TJ, Caspofungin Salvage Aspergillosis Study Group. Efficacy and safety of caspofungin for treatment of invasive aspergillosis in patients refractory to or intolerant of conventional antifungal therapy. Clin Infect Dis 2004; 39: 1563-1571
44. Manavathu EK, Cutright JL, Chandrasekar PH. Organism-dependent fungicidal activities of azoles. Antimicrob Agents Chemother 1998; 42: 3018-3021
45. Marr KA, Boeckh M, Carter RA, Kim HW, Corey L. Combination antifungal therapy for invasive aspergillosis. Clin Infect Dis 2004; 39: 797-802
46. Mora-Duarte J, Betts R, Rotstein C, Colombo AL, Thompson-Moya L, Smietana J, Lupinacci R, Sable C, Kartsonis N, Perfect J Caspofungin Invasive Candidiasis Study Group. Comparison of caspofungin and amphotericin B for invasive candidiasis. N Engl J Med 2002; 347: 2020-2029
47. th Interscience Conference on Antimicrobial Agents and Chemotherapy. Abstract 1108. American Society for Microbiology, Washington, DC 2000; 372
48. th Interscience Conference on Antimicrobial Agents and Chemotherapy. Abstract 838. American Society for Microbiology, Washington, DC 2000; 22
49. Ostrosky-Zeichner L, Oude Lashof AM, Kullberg BJ, Rex JH. Voriconazole salvage treatment of invasive candidiasis. Eur J Clin Microbiol Infect Dis 2003; 22: 651-655
50. Perfect JR, Marr KA, Walsh TJ, Greenberg RN, DuPont B, de la Torre-Cisneros J, Just-Nubling G, Schlamm HT, Lutsar I, Espinel-Ingroff A, Johnson E. Voriconazole treatment for less-common, emerging, or refractory fungal infections. Clin Infect Dis 2003; 36: 1122-1131
51. Pettengell K, Mynhardt J, Kluyts T, Lau W, Facklam D, Buell D, FK463 South African Study Group. Successful treatment of oesophageal candidiasis by micafungin: a novel systemic antifungal agent. Aliment Pharmacol Ther 2004; 20: 475-481
52. Pfaller MA, Messer SA, Boyken L, Tendolkar S, Hollis RJ, Diekema DJ. Geographic variation in the susceptibilities of invasive isolates of Candida glabrata to seven systemically active antifungal agents: a global assessment from the ARTEMIS Antifungal Surveillance Program conducted in 2001 and 2002. J Clin Microbiol 2004; 42: 3142-3146
53. Pfaller MA, Messer SA, Hollis RJ, Jones RN, Diekema DJ. In vitro activities of ravuconazole and voriconazole compared with those of four approved systemic antifungal agents against 6 970 clinical isolates of Candida spp. Antimicrob Agents Chemother 2002; 46: 1723-1727
54. Pfaller MA, Messer SA, Hollis RJ, Jones RN, Doern GV, Brandt ME, Hajjeh RA. In vitro susceptibilities of Candida bloodstream isolates to the new triazole antifungal agents BMS-207147, Sch 56592, and voriconazole. Antimicrob Agents Chemother 1998; 42: 3242-3244
55. rd Interscience Conference on Antimicrobial Agents and Chemotherapy. Abstract M-978. American Society for Microbiology, Washington, DC 2003; 450
56. Purkins L, Wood N, Ghahramani P, Greenhalgh K, Allen MJ, Kleinermans D. Pharmacokinetics and safety of voriconazole following intravenous- to oral-dose escalation regimens. Antimicrob Agents Chemother 2002; 46: 2546-2553
57. Purkins L, Wood N, Greenhalgh K, Allen MJ, Oliver SD. Voriconazole, a novel wide-spectrum triazole: oral pharmacokinetics and safety. Br J Clin Pharmacol 2003; 56 (Suppl 1): 10-16
58. Purkins L, Wood N, Greenhalgh K, Eve MD, Oliver SD, Nichols D. The pharmacokinetics and safety of intravenous voriconazole - a novel wide-spectrum antifungal agent. Br J Clin Pharmacol 2003; 56 (Suppl 1): 2-9
59. Ratanatharathorn V, Flynn P, Burik JA van, McSweeney P, Niederwieser D, Kontoyiannis D. Micafungin in combination with systemic antifungal agents in the treatment of refractory aspergillosis in bone marrow transplant patients. Abstract 2472. American Society of Hematology, Philadelphia 2002
60. Roffey SJ, Cole S, Comby P, Gibson D, Jezequel SG, Nedderman AN, Smith DA, Walker DK, Wood N. The disposition of voriconazole in mouse, rat, rabbit, guinea pig, dog, and human. Drug Metab Dispos 2003; 31: 731-741
61. Sable CA, Nguyen BY, Chodakewitz JA, DiNubile MJ. Safety and tolerability of caspofungin acetate in the treatment of fungal infections. Transpl Infect Dis 2002; 4: 25-30
62. Schwartz S, Thiel E. Update on the treatment of cerebral aspergillosis. Ann Hematol 2004; 83 (Suppl 1): 42-44
63. th Interscience Conference on Antimicrobial Agents and Chemotherapy. Abstract 18. American Society for Microbiology, Washington, DC 2000; 1
64. Steinbach WJ, Benjamin Jr DK, Kontoyiannis DP, Perfect JR, Lutsar I, Marr KA, Lionakis MS, Torres HA, Jafri H, Walsh TJ. Infections due to Aspergillus terreus: a multicenter retrospective analysis of 83 cases. Clin Infect Dis 2004; 39: 192-198
65. nd Interscience Conference on Antimicrobial Agents and Chemotherapy. Abstract A-1389. American Society for Microbiology, Washington, DC 2002; 19
66. Stone JA, Holland SD, Wickersham PJ, Sterrett A, Schwartz M, Bonfiglio C, Hesney M, Winchell GA, Deutsch PJ, Greenberg H, Hunt TL, Waldman SA. Single- and multiple-dose pharmacokinetics of caspofungin in healthy men. Antimicrob Agents Chemother 2002; 46: 739-745
67. Stone JA, Xu X, Winchell GA, Deutsch PJ, Pearson PG, Migoya EM, Mistry GC, Xi L, Miller A, Sandhu P, Singh R, deLuna F, Dilzer SC, Lasseter KC. Disposition of caspofungin: role of distribution in determining pharmacokinetics in plasma. Antimicrob Agents Chemother 2004; 48: 815-823
68. nd Interscience Conference on Antimicrobial Agents and Chemotherapy. Abstract M-892. American Society for Microbiology, Washington, DC 2002; 394
69. Burik JA van, Ratanatharathorn V, Stepan DE, Miller CB, Lipton JH, Vesole DH, Bunin N, Wall DA, Hiemenz JW, Satoi Y, Lee JM, Walsh TJ, National Institute of Allergy and Infectious Diseases Mycoses Study Group. Micafungin versus Fluconazole for prophylaxis against invasive fungal infections during neutropenia in patients undergoing hematopoietic stem cell transplantation. Clin Infect Dis 2004; 39: 1407-1416
70. th Interscience Conference on Antimicrobial Agents and Chemotherapy. Abstract 1107. American Society for Microbiology, Washington, DC 2000; 372
71. Villanueva A, Arathoon EG, Gotuzzo E, Berman RS, DiNubile MJ, Sable CA. A randomized double-blind study of caspofungin versus amphotericin for the treatment of candidal esophagitis. Clin Infect Dis 2001; 33: 1529-1535
72. Villanueva A, Gotuzzo E, Arathoon EG, Noriega LM, Kartsonis NA, Lupinacci RJ, Smietana JM, DiNubile MJ, Sable CA. A randomized double-blind study of caspofungin versus fluconazole for the treatment of esophageal candidiasis. Am J Med 2002; 113: 294-299
73. Voriconazol package circular Vfend (Fachinformation). Version 12/2003. BPI, Aulendorf, Germany 2003
74. nd Interscience Conference on Antimicrobial Agents and Chemotherapy. Abstract M-896. American Society for Microbiology, Washington, DC 2002; 395
75. Walsh TJ, Karlsson MO, Driscoll T, Arguedas AG, Adamson P, Saez-Llorens X, Vora AJ, Arrieta AC, Blumer J, Lutsar I, Milligan P, Wood N. Pharmacokinetics and safety of intravenous voriconazole in children after single- or multiple-dose administration. Antimicrob Agents Chemother 2004; 48: 2166-2172
76. Walsh TJ, Lutsar I, Driscoll T, Dupont B, Roden M, Ghahramani P, Hodges M, Groll AH, Perfect JR. Voriconazole in the treatment of aspergillosis, scedosporiosis and other invasive fungal infections in children. Pediatr Infect Dis J 2002; 21: 240-248
77. Walsh TJ, Pappas P, Winston DJ, Lazarus HM, Petersen F, Raffalli J, Yanovich S, Stiff P, Greenberg R, Donowitz G, Schuster M, Reboli A, Wingard J, Arndt C, Reinhardt J, Hadley S, Finberg R, Laverdiere M, Perfect J, Garber G, Fioritoni G, Anaissie E, Lee J, National Institute of Allergy and Infectious Diseases Mycoses Study Group. Voriconazole compared with liposomal amphotericin B for empirical antifungal therapy in patients with neutropenia and persistent fever. N Engl J Med 2002; 346: 225-234
78. Walsh TJ, Teppler H, Donowitz GR, Maertens JA, Baden LR, Dmoszynska A, Cornely OA, Bourque MR, Lupinacci RJ, Sable CA, dePauw BE. Caspofungin versus liposomal amphotericin B for empirical antifungal therapy in patients with persistent fever and neutropenia. N Engl J Med 2004; 351: 1391-1402
79. Wiederhold NP, Kontoyiannis DP, Chi J, Prince RA, Tam VH, Lewis RE. Pharmacodynamics of caspofungin in a murine model of invasive pulmonary aspergillosis: evidence of concentration-dependent activity. J Infect Dis 2004; 190: 1464-1471
80. th Interscience Conference on Antimicrobial Agents and Chemotherapy. Abstract M-1682. American Society for Microbiology, Washington DC 2004; 427